Afleveringen
-
Our little spin off of our time at JPM!
Big announcements and exclusives! Here we have David Happel, CEO of Sagimet Biosciences
Listen to hear how they've been doing.
-
Welcome to the BioHub podcast where we interview the top minds from across the Biotech and Pharma industry.
I’m joined by Gwen Acton, CEO of Vivo Group and an expert in leadership development for scientists, engineers, and biotech professionals.
Gwen has had a fascinating career—she earned a PhD from MIT, was a faculty member at Harvard, ran operations at the Whitehead Institute during the Human Genome Project, and has helped thousands of technical experts become stronger leaders.
Now, she’s adding “author” to her resume with a brand-new book on leadership, and today, we’re diving into why leadership is so crucial in biotech, how it’s evolved, and what inspired her to write it.
Enjoy and stay tuned
-
Zijn er afleveringen die ontbreken?
-
Welcome to the BioHub podcast where we interview the top minds from across the Biotech and Pharma industry.Today we're joined by David De Graaf, CEO of Co-Founder of Reverb TherapeuticsDavid has an incredible background, with positions at companies such as AstraZeneca, Pfizer, Apple Tree Partners & Boehringer Ingelheim as well being at the helm of multiple successful biotechs. In this episode, we dive into his journey, building out seed stage biotech's from scratch as well as the Canadian Biotech scene
-
Welcome to the BioHub podcast where we interview the top minds from across the Biotech and Pharma industry.
I’m joined by Judy Chou, CEO of AltruBio—one of the mostexciting biotech companies out there, especially after closing the largest Series B in biotech over the last four years.
Judy has an incredible background, having led global biotechat Bayer, held leadership roles at Pfizer, and served as research faculty at Harvard. Now, as the CEO of AltruBio, she’s driving the company’s mission to develop first-in-class immune modulators for autoimmune and inflammatorydiseases.
In this episode, we dive into her journey, how AltruBio isthriving in a tough market, and what’s ahead for the company in 2024. Let’s get into it!
Enjoy and stay Tuned.
-
Welcome to the BioHub podcast where we interview the top minds from across the Biotech and Pharma industry.
I’m joined by Aoife Brennan, CEO of Climb Bio—a company at the cutting edge of pioneering new approaches to cell and gene therapy.
Aoife is a seasoned biotech leader with a track record of driving innovation. Before joining Climb Bio, she was the CEO of Synlogic, where she led the company through critical clinical advancements in engineered probiotic medicines.
With a background in medicine and deep experience in biotech strategy, she has a unique perspective on bridging science and business to create transformative therapies.
In this episode, we talk about her journey, what makes Climb Bio’s approach different, and how she’s navigating leadership in an ever-evolving industry.
Enjoy and stay Tuned.
-
Thank you for tuning into another episode of Bio Hub! Today, we have the privilege of hosting Shalabh Gupta, a seasoned leader in the biotech industry and the current Founder, Chairman & CEO of Unicycive Therapeutics. Shalabh's experience is vast, spanning over two decades in leadership roles across the biotech landscape. He has previously served as CEO of Globavir Biosciences and CEO, Founder, Chairman and of BioCycive.Now, at the helm of Unicycive Therapeutics, Unicycive who are focused on developing new treatment options for patients with renal diseases, as kidney disease remains a major global health concer.
-
Welcome to the BioHub podcast where we interview the top minds from across the Biotech and Pharma industry.
I’m joined by Iain Kilty, CEO of Sitryx, a biotech pushing boundaries in immunology and inflammation.
Iain’s journey is fascinating—after 22 years at Pfizer, leading global drug discovery efforts, he transitioned into biotech, taking on the CSO role at Sitryx before stepping up as CEO. Now, he’s leading the charge as Sitryx enters the clinic, a huge milestone for any company.
In this episode, we dive into:
The science behind Sitryx’s breakthrough workThe UK biotech scene vs. the US—fundraising, growth, and challengesWhat’s next for Sitryx as they push toward transforming patient careEnjoy and stay Tuned.
-
Welcome to the BioHub podcast where we interview the top minds from across the Biotech and Pharma industry.
I’m joined by John Mumm, CEO of Deka Biosciences—a company breaking new ground in cytokine therapies for cancer and inflammatory diseases.
John is a true veteran of biotech, with over 30 years of experience in immunotherapy research. He’s spent his career working to unlock the potential of IL-10 and cytokines, tackling one of drug development’s biggest challenges. After leadership roles at MedImmune, and ARMO BioSciences, he founded Deka to bring a fresh approach to cytokine-based treatments.
Today, we dive into John’s journey as a three-time biotech founder, the fast-moving progress at Deka, and why cytokines have been so tough to crack—until now. Plus, we get into mindset, motivation, and what it takes to build a company that lasts.
Enjoy and Stay Tuned.
-
Welcome to the BioHub podcast where we interview the top minds from across the Biotech and Pharma industry.Melissa Sherman, CEO of MOBILion Systems—a true trailblazer shaking up separation science.Melissa was employee number one and has since raised $120M, built a world-class team, and launched Mobi, a technology that’s transforming how we analyze molecules. Think of it like upgrading from an old film camera to the latest high-definition digital—faster, clearer, and game-changing for drug developers.We dive into her inspiring journey of building MOBILion from the ground up, creating a winning company culture, and why she believes this tech is the future of separation science.Enjoy and Stay Tuned.
-
Our little spin off of our time at JPM!
Big announcements and exclusives! Here we have Stella Vnook, CEO of Likarda.
Listen to hear how they've been doing.
-
Our little spin off of our time at JPM!
Big announcements and exclusives! Here we have Patrick Alexandre, CEO of Crossject.
Listen to hear how they've been doing.
-
Thank you for tuning into another episode of Bio Hub! Today, we have the privilege of hosting David Esposito, a seasoned leader in the biotech industry and the CEO of ONL Therapeutics. David's experience is vast, spanning over two decades in leadership roles across the biotech landscape. He has previously served as President and CEO of Armune Biosciences, VP Commercial Operations at Thermo Fisher, and Executive Director Commercial Strategy at Merck.
-
Our little spin off of our time at JPM!
Big announcements and exclusives! Here we have Glen Gowers, CEO and co-Founder of Basecamp Research.
Listen to hear how they've been doing.
-
Our little spin off of our time at JPM!
Big announcements and exclusives! Here we have Simrit Parmar, Founder of Cellenkos.
Listen to hear how they've been doing.
-
Our little spin off of our time at JPM!
Big announcements and exclusives! Here we have Angelos Stergiou, CEO of Sellas Life Sciences
Listen to hear how they've been doing.
-
Our little spin off of our time at JPM!
Big announcements and exclusives! Here we have Michael Parini, CEO of Spur Therapeutics.
Listen to hear how they've been doing.
-
Our little spin off of our time at JPM!
Big announcements and exclusives! Here we have Yang Liu, CEO & CSO of OncoC4.
Listen to hear how they've been doing.
-
The first of our little spin off and time at JPM!
Big announcements and exclusives! Here we have Adrian Rawcliffe, CEO of Adaptimmune.
Listen to hear how they've been doing.
-
Welcome to the BioHub podcast where we interview the top minds from across the Biotech and Pharma industry.
We have a special guest—Michael Castagna, CEO of MannKind Corporation. Michael has over 25 years of experience in marketing, sales, and business development across both Fortune 500 companies and biotech startups.
Under his leadership, MannKind has grown into a major player in the field of endocrine and orphan lung diseases, bringing innovative therapies like Afrezza®, the only inhaled ultra-rapid-acting insulin, to market.
In this episode, Michael shares his journey, the challenges and triumphs of leading MannKind, and the future of the company’s groundbreaking technologies.
We also dive deep into his passion for turning around struggling companies and the lessons he’s learned from navigating the biotech landscape.
Enjoy and Stay Tuned.
-
Welcome to the BioHub podcast where we interview the top minds from across the Biotech and Pharma industry.
We are thrilled to welcome Dr. Kevin Warner, Senior Vice President of Medical Affairs strategy and engagement at Heron Therapeutics.
Dr. Warner brings 2 decades of experience in clinical and infusion pharmacy, with a special focus on pharmacokinetics, pharmacodynamics, and antimicrobial stewardship. He has been instrumental in co-developing the VT-X7 intra-articular antibiotic irrigation therapy and has played a crucial role in numerous committees dedicated to improving patient care.
At Heron Therapeutics, Dr. Warner is at the forefront of enhancing recovery after surgery and developing innovative pharmaceutical products using their proprietary Biochronomer™ drug delivery platform. With his extensive background and dedication to advancing patient care, Dr. Warner is a true leader in the pharmaceutical industry.
We’re excited to dive into his journey, explore Heron’sgroundbreaking work, and discuss the future of pharmaceutical innovation.
Enjoy and stay tuned.
- Laat meer zien
